


NNVC (NanoViricides, Inc.): The Hidden Antiviral Giant Poised to Explode

A single drug. Vast markets. Breakthrough mechanism. The opportunity is now.



Imagine a world where one drug works like an “antiviral antibiotic”— broad, safe, effective against some of the world’s most devastating viral threats. Now imagine that company is trading at a tiny ~\$23M market cap, with its first human trials already behind it, and major catalysts about to unfold.

That company is NanoViricides (NNVC).

NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells

Nanoviricides, Inc. is close to having a single drug NV-387 for the treatment of all of the "triple-demic" respiratory viruses - Coronaviruses, RSV, and Influenza A, which would be a revolutionary achievement!

ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate

[CHECK OUT THE INVESTOR PRESENTATION HERE](#)

[Watch My Research Video Here](#)

Why This Is Urgent

- Viral outbreaks don't wait. When the next Bird Flu spillover or more lethal mpox clade spreads, demand will be immediate and global.
 - NV-387 is one of the few therapeutics that could be stockpiled, administered orally, effective broadly—even as viruses mutate. That's rare in the antiviral world.
 - The company is small now. Major progress (Phase II initiation, animal/influenza/virus-escape data, manufacturing scale) could lead to outsized value appreciation before most investors even know what NV-387 is.
-

The Investment Edge

- With a modest valuation and limited capital needed (especially if non-dilutive funding or partnerships are secured), there is **high optionality**: a win in any one major indication could meaningfully shift the valuation.
 - The science suggests durability: viral mutation escape is a perennial problem; NV-387 is built to withstand that.
 - Infrastructure (IP, manufacturing facility, pipeline breadth) already in place reduces lead time relative to many clinical-stage small biotechs starting from scratch.
 - Market signals (stock behavior, regulatory clearances, trial preparations) indicate momentum is building now.
-

The Big Idea

What if one antiviral could sidestep the arms race against viral mutations—treat *COVID, RSV, influenza, mpox, bird flu, even measles*—without needing vaccines, antibodies, or constant reformulation?

NanoViricides (NNVC) is developing **NV-387**, a host-mimetic, broad-spectrum antiviral with a mechanism unlike anything else—decoy trapping, virus destruction, resistance nearly impossible. And it's already showing animal/Phase I human safety success.

Small company. Huge possibility. The inflection point is real and unfolding.

Why NNVC Could Be a Big Deal (Explained Super Simple)

What does NNVC do?

NNVC is a tiny company that makes a new kind of medicine. Instead of fighting just one sickness, their medicine can fight lots of different viruses at once.

Think of it like a giant bug zapper for viruses. The virus runs into it, gets trapped, and can't hurt people anymore.

What's their main medicine?

It's called NV-387 (you can think of it as "Virus Zapper 387"). It already passed a safety test in people — no bad side effects. That means they can try it on sick people next.

Why is this important?

- **Monkeypox (Mpox):** Right now, there's no good medicine for it. NNVC's drug could be the first.
 - **Other sicknesses too:** RSV, flu, COVID, even scary bird flu. One drug for many problems.
 - **Governments want answers:** The World Health Organization says Mpox is still an emergency. Countries are looking for treatments.
-

Why is this exciting for investors?

- The whole company is worth about \$23 million (tiny).
 - Just the RSV medicine market alone is worth \$2 billion+. That's *billion with a "B"*.
 - If their drug works for even one sickness, the company could grow a LOT.
-

What makes NNVC special?

- They have their own factory to make the medicine. Most small companies don't — this saves time and money. And once approved, it saves more time and money.
 - They're working on easy versions, like gummy medicines. Kids and adults could take them without a shot. (without a shot)
 - Their medicine is like an antibiotic for viruses — it could work even if the virus mutates and changes.
-

17 What's happening soon?

- Starting the next trial in people with monkeypox.
 - More news about testing their drug against flu, RSV, and COVID.
 - Updates expected this fall (Sept 2025).
-

Why is it urgent?

Viruses spread fast. Governments and hospitals need something new right now. If NNVC shows their drug works, everyone will want it — and the stock could jump.

👉 In short:

NNVC is like a tiny treasure chest right now. If their “virus zapper” medicine works, it could unlock a gold mine of opportunity.

Large Market Size - over \$40B total by 2013 ⁽¹⁾

Viral Disease	Mkt Size 2013	NNVC Opportunity
HIV/AIDS	\$ 21 Billion (B)	HIV-Cide a “Functional Cure”?
Influenza, Bird Flu	\$ 7 B	Resistance to current drugs widespread
Viral Diseases of Ext. Eye	\$ 1 B	No current non-toxic drugs ⁽²⁾
Hepatitis C	\$ 6 B	Current therapies not very effective
Herpes- Cold Sores and Genital	\$ 2 B	
Dengue, Rabies, other	\$ 1 B(combined)	Rapidly increasing Developing World markets ⁽²⁾
Ebola/Marburg/VHF	\$ 1 B(combined)	Biodefense, Biosecurity ⁽²⁾

(1). Jain Pharma Biotech. March 2009. “Antiviral Therapeutics: Technologies, Companies & Markets”, by Prof. K. K. Jain, MD, FRACS, FFPM. Basel, Switzerland. (2). Estimates based on the Jain Report, and a report commissioned by the Company for more detailed analyses of these special markets. March 2009.

Why NNVC Stands Out Now

1. Phase II Is Next

Their lead candidate NV-387 already completed Phase I in humans with zero reportable adverse events. Phase II is now advancing in mpox, one of the fastest-growing unmet global viral threats.

2. Unmet Need in Mpox = First-Mover Advantage

Currently, no FDA-approved mpox treatment exists. Competitor drugs have failed to show efficacy. If NV-387 succeeds, it could be first-in-class.

3. Global Spotlight

The World Health Organization renewed its mpox Public Health Emergency in 2025. Governments are actively seeking new solutions—funding, fast-tracking, and spotlighting therapeutics like NV-387.

4. Broad-Spectrum Platform

NV-387 is designed to work against RSV, Influenza, Coronaviruses (including COVID/long COVID), and Orthopoxviruses (mpox/smallpox). One pipeline, multiple blockbuster markets.

5. Massive Market Opportunity vs. Tiny Valuation

- **Market Cap: ~\$23M (TINY Free Float)**
- **RSV Market: \$2B+ and growing**
- **Influenza & COVID Markets: Billions more**
- **Mpox/Smallpox: Strategic national stockpile opportunity**

Even modest traction could re-rate NNVC by multiples.

6. In-House Manufacturing Advantage

Unlike most nano-caps, NNVC owns a cGMP-capable facility in Shelton, CT. This allows them to produce at scale without costly outsourcing delays—a rare asset for a company this size.

7. Safety Already Proven

Completed Phase I showed NV-387 is safe and well-tolerated, giving it the green light to pursue multiple outpatient viral indications.

8. Growing Disease Burden = Growing Demand

Despite vaccines, RSV and flu continue to burden healthcare systems. Long COVID adds a new, multi-billion-dollar therapeutic market. A broad antiviral fills the exact gap vaccines can't cover.

9. Investor & Partnering Visibility in 2025

The company is actively presenting at major industry events (BIO Boston, LSX Congress Boston) to attract partnerships, collaborations, and potential non-dilutive funding.

10. High-Impact Catalysts Imminent

- Mpx Phase II trial initiation
 - NV-387 expansion into RSV, COVID, Influenza
 - New IND for shingles candidate (NV-HHV-1)
 - Company updates around Sept. 25, 2025 earnings
-



Key Competitive Advantages & Differentiators

- **Host-mimetic decoy mechanism:** NV-387 mimics **sulfated proteoglycans (HSPG/SPG)**, tricking viruses to bind to it, becoming “trapped” and destroyed. This sidesteps the usual mutation escape path.
- **Broad spectrum:** Effective (in preclinical/animal studies) against:
 - Covid/SARS-CoV-2 (and variants)
 - Influenza (multiple strains, including H3N2 and bird flu H5N1/H7N9)
 - RSV (curing lethal lung infection in animals with indefinite survival)
 - Mpx / smallpox / orthopox viruses
 - Measles (emerging outbreak risk), with rationale for effectiveness based on shared viral entry pathways (HSPG)

- **Multiple delivery forms:** Oral (including “gummies” in development), injectable, inhalation. Flexibility in administration broadens market reach (pediatrics, adults, outpatient vs inpatient) and eases adoption.
- **Phase I safety profile strong:** Completed Phase Ia/Ib in healthy subjects, **no reported adverse events**, even at highest & repeated doses.
- **Regulatory progress:**
 - NV-387 cleared by the National Ethics Committee of the Democratic Republic of Congo (DRC) to move forward to Clinical Trial Application (CTA) for Phase II mpox study.
 - CRO engagement, trial site selection (University of Kinshasa) in process.
- **Manufacturing & infrastructure:** Has its own cGMP facility in Shelton, CT. Orally deliverable gummy forms suggest consumer-friendly options.
- **Strategic IP & platform breadth:** Exclusive licenses via TheraCour for a wide array of viruses; parallel pipeline (e.g. NV-HHV-1 for shingles; potential applications for herpes, dengue, Ebola etc.)



Financial Snapshot & Capital Position (Lean, But Hungry)

- Cash & equivalents as of March 31, 2025: ~\$2.73 million. Current P&E heavy on its cGMP facility.
- Liabilities relatively low (~\$1.2 million), but **net cash available for operations** (post liabilities) ~ **\$4.5-\$5.7 million**, including a \$3 million line of credit from the founder.
- Burn rate: ~\$6.78 million used in first three quarters of fiscal year, heavily driven by trial prep & R&D.



Imminent Catalysts / What’s Coming, Why It Could Tick Up Fast

Catalyst

Timing & Significance

Phase II Clinical Trial Initiation for Mpox (DRC)

With CNES approval in hand, the detailed CTA filing is underway; when announced, this will be a major step.

Trial Site Activation & Enrollment

University of Kinshasa already selected, CRO engaged. Once first-patient-in or dosing begins, this drives visibility.

Influenza / Bird Flu / Measles Preclinical Readouts

Animal data already strong vs existing antivirals; these readouts would support expansion into other massive infectious disease markets.

Regulatory Approvals & Non-Dilutive Funding

Oral formulation options + manufacturing capacity + public health urgency (pandemics / outbreaks) may unlock grants, stockpile contracts.

Public & Market Awareness Surge

With stock showing strength technically, conference presentations, media coverage, and new data releases expected – attention could snowball.

Market Size & Opportunity

- **Respiratory “triple-demic” (COVID + RSV + Influenza):** Huge recurring demand across seasons; multiple billions per indication.
 - **Mpox / orthopox / smallpox / biodefense markets:** Governments and NGOs need effective options. Current approved treatments have failed or are limited.
 - **Bird Flu (H5N1, H7N9) risk escalating:** Animal spillovers increasing; NV-387’s preclinical strength here is a differentiator.
 - **Measles outbreaks:** Surge driven by vaccine hesitancy, waning coverage. No approved antiviral for measles. NV-387 could fill that gap.
-

Why This Is Urgent

- Viral outbreaks don’t wait. When the next Bird Flu spillover or more lethal mpox clade spreads, demand will be immediate and global.
 - NV-387 is one of the few therapeutics that could be stockpiled, administered orally, effective broadly—even as viruses mutate. That’s rare in the antiviral world.
 - The company is small now. Major progress (Phase II initiation, animal/influenza/virus-escape data, manufacturing scale) could lead to outsized value appreciation before most investors even know what NV-387 is.
-

The Investment Edge

- With a modest valuation and limited capital needed (especially if non-dilutive funding or partnerships are secured), there is **high optionality**: a win in any one major indication could meaningfully shift the valuation.

- The science suggests durability: viral mutation escape is a perennial problem; NV-387 is built to withstand that.
 - Infrastructure (IP, manufacturing facility, pipeline breadth) already in place reduces lead time relative to many clinical-stage small biotechs starting from scratch.
 - Market signals (stock behavior, regulatory clearances, trial preparations) indicate momentum is building now.
-

Why the Timing Is Critical

With Phase II around the corner, WHO and governments spotlighting mpox, and global demand for antivirals only growing—the **window to act before broad investor awareness is narrow**.

NanoViricides is positioned as a true **high-growth opportunity hiding in plain sight**.

NEWS

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

Jul 14, 2025

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate

Jul 1, 2025

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 18, 2025

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 22, 2025

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Ready to Combat Measles Outbreaks, and to Tackle Bird Flu

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 14, 2025

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

May 8, 2025

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 29, 2025

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Apr 14, 2025

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 11, 2025

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Mar 4, 2025

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Feb 11, 2025

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 29, 2025

DISCLAIMER

This content is for educational and informational purposes only. I am not a licensed financial advisor, registered investment advisor (RIA), or broker-dealer, and nothing in this content constitutes financial, investment, tax, or legal advice. No material shared via video, email, website, or social media constitutes a recommendation, solicitation, or endorsement to buy or sell any securities, futures, options, or other financial instruments. Trading and investing involve substantial risk and may not be suitable for everyone. You could lose some or all of your investment. Past performance is not indicative of future results. Any trading strategies, trade alerts, or examples discussed are strictly for illustration and education purposes only, and are based on personal opinion and experience. These are not trade recommendations and should not be relied upon for making investment decisions. Testimonials or user-submitted success stories may be included and represent individual experiences. These results are not verified, typical, or guaranteed. Individual outcomes vary depending on many factors, including but not limited to experience, capital, discipline, and market conditions. Affiliate links or compensation may be received in connection with some products or services mentioned. These relationships do not influence the opinions expressed or the integrity of the content. All viewers and readers are advised to conduct their own due diligence and consult with a licensed financial professional before making any financial decisions. Use of this content is at your own risk. By engaging with this material, you agree to hold the creator harmless from any financial losses or legal issues that may arise. This is a paid advertisement and is intended for informational and educational purposes only. It is a publication of Infinite Pursuit LLC, wholly owned and operated by ItsMikePoarch. Infinite Pursuit LLC is engaged in the business of marketing and advertising publicly traded companies for monetary compensation. Infinite Pursuit LLC has been compensated five thousand USD by a third party interactive offers for a one day marketing campaign featuring nncv beginning September eighteenth two thousand twenty five. Never invest in any stock featured in our communications unless you can afford to lose your entire investment. We are not registered investment advisors, broker-dealers, or licensed financial professionals. Nothing in this communication should be construed as personalized investment advice or a recommendation to buy or sell any security. By reading this content or interacting with our platforms, you agree to hold Infinite Pursuit LLC, ItsMikePoarch, and all associated parties harmless from any and all liability, losses, or damages that may result. Investing in micro-cap and growth securities is highly speculative and carries a high degree of risk. This communication may contain forward-looking statements, which are based on expectations, estimates, and projections as of the date of publication. Forward-looking statements involve risks and uncertainties, and actual results may differ materially. Words such as "expects," "believes," "projects," "anticipates," and similar terms identify such statements. Information provided is sourced from public data or directly from the featured company and is believed to be reliable, but no guarantee is made regarding its accuracy or completeness. This is not an offer or solicitation to buy or sell securities. We encourage all readers to conduct independent research and consult with a licensed financial advisor before investing. This communication complies with the CAN-SPAM Act of 2003. Full Terms of Use and Disclosure Policy available at: <https://docs.google.com/document/d/1JPpcN7J0y3voXGmSVxhK71b18wQ-LyWfEwfeyCVNK8M/edit?usp=sharing>